<?xml version='1.0' encoding='utf-8'?>
<document id="21698600"><sentence text="Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat."><entity charOffset="28-40" id="DDI-PubMed.21698600.s1.e0" text="ketoconazole" /></sentence><sentence text="Hyperlipidemia (HL) was previously shown to lower liver uptake of the more potent (-) enantiomer of ketoconazole (KTZ) in rat"><entity charOffset="100-112" id="DDI-PubMed.21698600.s2.e0" text="ketoconazole" /><entity charOffset="114-117" id="DDI-PubMed.21698600.s2.e1" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s2.e0" e2="DDI-PubMed.21698600.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s2.e0" e2="DDI-PubMed.21698600.s2.e1" /></sentence><sentence text=" The current study examined the possible modifying influence of experimental HL on a KTZ pharmacokinetic interaction with midazolam (MDZ)"><entity charOffset="122-131" id="DDI-PubMed.21698600.s3.e0" text="midazolam" /><entity charOffset="133-136" id="DDI-PubMed.21698600.s3.e1" text="MDZ" /><entity charOffset="85-87" id="DDI-PubMed.21698600.s3.e2" text="KTZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s3.e2" e2="DDI-PubMed.21698600.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21698600.s3.e2" e2="DDI-PubMed.21698600.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s3.e2" e2="DDI-PubMed.21698600.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21698600.s3.e0" e2="DDI-PubMed.21698600.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s3.e0" e2="DDI-PubMed.21698600.s3.e1" /></sentence><sentence text=" Normolipidemic and hyperlipidemic rats were administered a single intravenous dose of MDZ (5 mg/kg) with or without a single oral dose of racemic KTZ (40 mg/kg)"><entity charOffset="147-149" id="DDI-PubMed.21698600.s4.e0" text="KTZ" /><entity charOffset="87-89" id="DDI-PubMed.21698600.s4.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s4.e1" e2="DDI-PubMed.21698600.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21698600.s4.e1" e2="DDI-PubMed.21698600.s4.e0" /></sentence><sentence text=" Serial blood samples were collected over 8 h following MDZ injections via jugular vein cannulas"><entity charOffset="56-58" id="DDI-PubMed.21698600.s5.e0" text="MDZ" /></sentence><sentence text=" Plasma was jointly assayed for MDZ and KTZ concentrations using a validated assay"><entity charOffset="40-42" id="DDI-PubMed.21698600.s6.e0" text="KTZ" /><entity charOffset="32-34" id="DDI-PubMed.21698600.s6.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s6.e1" e2="DDI-PubMed.21698600.s6.e1" /><pair ddi="false" e1="DDI-PubMed.21698600.s6.e1" e2="DDI-PubMed.21698600.s6.e0" /></sentence><sentence text=" MDZ mean clearance (CL) was unchanged by KTZ coadministration"><entity charOffset="42-44" id="DDI-PubMed.21698600.s7.e0" text="KTZ" /><entity charOffset="1-3" id="DDI-PubMed.21698600.s7.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s7.e1" e2="DDI-PubMed.21698600.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21698600.s7.e1" e2="DDI-PubMed.21698600.s7.e0" /></sentence><sentence text=" HL caused a significantly 61% lower MDZ-unbound fraction and decreases in volume of distribution (VD) but by itself had no effect on MDZ CL"><entity charOffset="37-39" id="DDI-PubMed.21698600.s8.e0" text="MDZ" /><entity charOffset="134-136" id="DDI-PubMed.21698600.s8.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s8.e0" e2="DDI-PubMed.21698600.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s8.e0" e2="DDI-PubMed.21698600.s8.e1" /></sentence><sentence text=" This suggested that MDZ could bind to lipoproteins"><entity charOffset="21-23" id="DDI-PubMed.21698600.s9.e0" text="MDZ" /></sentence><sentence text=" With KTZ coadministered to hyperlipidemic rats, there were significant decreases in MDZ CL and VD"><entity charOffset="6-8" id="DDI-PubMed.21698600.s10.e0" text="KTZ" /><entity charOffset="85-87" id="DDI-PubMed.21698600.s10.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s10.e0" e2="DDI-PubMed.21698600.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s10.e0" e2="DDI-PubMed.21698600.s10.e1" /></sentence><sentence text=" HL caused a decrease in unbound plasma fraction of oral KTZ but no significant difference in its pharmacokinetics"><entity charOffset="57-59" id="DDI-PubMed.21698600.s11.e0" text="KTZ" /></sentence><sentence text=" HL caused a more pronounced KTZ-associated inhibition of MDZ CL"><entity charOffset="29-31" id="DDI-PubMed.21698600.s12.e0" text="KTZ" /><entity charOffset="58-60" id="DDI-PubMed.21698600.s12.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.21698600.s12.e0" e2="DDI-PubMed.21698600.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21698600.s12.e0" e2="DDI-PubMed.21698600.s12.e1" /></sentence><sentence text=" This may be related to the decrease of MDZ's unbound fraction and perhaps to attenuation of CYP3A by HL in the rat"><entity charOffset="40-42" id="DDI-PubMed.21698600.s13.e0" text="MDZ" /></sentence><sentence text="" /></document>